PA
VRDN icon

Perceptive Advisors’s Viridian Therapeutics VRDN Stock Holding History

Perceptive Advisors’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.7M Sell
581,980
-588,849
-50% -$9.49M 0.16% 78
2026
Q1 		$22.9M Sell
1,170,829
-1,871,874
-62% -$55.6M 0.45% 50
2025
Q4 		$94.7M Buy
3,042,703
+1,580,303
+108% +$43.3M 1.69% 18
2025
Q3 		$31.6M Buy
1,462,400
+1,014,893
+227% +$18.3M 0.91% 33
2025
Q2 		$6.26M Sell
447,507
-212,155
-32% -$2.88M 0.23% 63
2025
Q1 		$8.89M Sell
659,662
-826,846
-56% -$14.1M 0.31% 57
2024
Q4 		$28.5M Sell
1,486,508
-1,326,157
-47% -$28.8M 0.79% 35
2024
Q3 		$64M Buy
2,812,665
+1,180,837
+72% +$19.3M 1.35% 25
2024
Q2 		$21.2M Sell
1,631,828
-2,025,271
-55% -$28M 0.51% 54
2024
Q1 		$64M Buy
3,657,099
+1,926,887
+111% +$37.4M 1.12% 31
2023
Q4 		$37.7M Buy
1,730,212
+719,007
+71% +$11.4M 0.84% 35
2023
Q3 		$15.5M Sell
1,011,205
-765,181
-43% -$14.6M 0.52% 52
2023
Q2 		$42.3M Buy
1,776,386
+40,000
+2% +$1.03M 1.22% 24
2023
Q1 		$44.2M Buy
1,736,386
+515,811
+42% +$16.5M 1.3% 21
2022
Q4 		$35.7M Hold
1,220,575
– – 1% 29
2022
Q3 		$25M Buy
1,220,575
+248,743
+26% +$4.47M 0.73% 37
2022
Q2 		$11.2M Sell
971,832
-451,221
-32% -$6.06M 0.35% 56
2022
Q1 		$26.3M Hold
1,423,053
– – 0.53% 47
2021
Q4 		$28.1M Buy
1,423,053
+53
+0% +$987 0.43% 54
2021
Q3 		$23.4M Buy
1,423,000
+628,494
+79% +$9.22M 0.34% 65
2021
Q2 		$14.5M Buy
+794,506
New +$13.6M 0.19% 98

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Perceptive Advisors's VRDN Position: Q2 2026 in Review

Perceptive Advisors reduced its Viridian Therapeutics (VRDN) stake by 50% in Q2 2026, selling an estimated $9.49M and leaving 581,980 shares worth $10.7M. The position accounts for 0.16% of the portfolio, ranked #78.

Perceptive Advisors first reported a position in VRDN in Q2 2021 and has held it in 21 quarters since. The position peaked at $94.7M in Q4 2025. 212 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Perceptive Advisors held 581,980 shares of Viridian Therapeutics worth $10.7M as of Q2 2026.
  • Perceptive Advisors sold 588,849 Viridian Therapeutics shares in Q2 2026, an estimated $9.49M.
  • Viridian Therapeutics made up 0.16% of Perceptive Advisors's portfolio in Q2 2026, its #78 holding.
  • Perceptive Advisors first reported a position in Viridian Therapeutics in Q2 2021 and has held it in 21 quarters since.
  • Perceptive Advisors's Viridian Therapeutics position peaked at $94.7M in Q4 2025.
  • 212 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Perceptive Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.